Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Neurosurgical Review
Erschienen in: Neurosurgical Review 1/2012

01.01.2012 | Review

Current therapeutic options and novel molecular markers in skull base chordomas

verfasst von: Filippo Gagliardi, Nicola Boari, Paola Riva, Pietro Mortini

Erschienen in: Neurosurgical Review | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Chordomas are extremely rare tumours. They arise in the spheno-occipital region in 35% of cases. Chordomas usually present benign histopathological features but often exhibit a malignant clinical behaviour. Radical surgical removal and high-dose radiation therapy seem to be effective in tumour control and to improve survival rate. Despite the advancements in microsurgical techniques and the development of radiation therapies, clival chordomas still represent a challenge. Nevertheless it appears that chordomas that have been resected to the same extent and that received post-operative radiotherapy might exhibit different rates of regrowth. This result supports the hypothesis that the recurrence rate of chordomas might be dependent on biological variables other than the extent of resection and the post-operative radiotherapy. Genetic and molecular studies on oncogenesis of chordomas are still limited, but they represent the basis for the development of molecular targeted therapies. We present a review of the current knowledge about skull base chordomas biology, therapeutic options and related clinical outcome.
Literatur
1.
Al-Mefty O, Borba LA (1997) Skull base chordomas: a management challenge. J Neurosurg 86(2):182–189PubMedCrossRef
2.
Amendola BE, Amendola MA, Oliver E et al (1986) Chordoma: role of radiation therapy. Radiology 158:839–843PubMed
3.
4.
Austin JP, Urie MM, Cardenosa G et al (1993) Probabile causes of recurrence in patients with chordoma and chondrosarcoma of the base of skull and cervical spine. Int J Radiat Oncol Biol Phys 25:439–444PubMedCrossRef
5.
Austin-Seymour M, Munzenrider J, Goitein M et al (1989) Fractionated proton radiation therapy of chordoma and low-grade chondrosarcoma of the base of the skull. J Neurosurg 70:13–17PubMedCrossRef
6.
Benk V, Liebsch NJ, Munzenrider JE et al (1995) Base of skull and cervical spine chordomas in children treated by high-dose irradiation. Int J Radiat Oncol Biol Phys 31:577–581PubMedCrossRef
7.
Berson AM, Castro JR, Petti P et al (1988) Charged particle irradiation of chordoma and chondrosarcoma of the base of skull and cervical spine: the Lawrence Berkeley Laboratory experience. Int J Radiat Oncol Biol Phys 15:559–565PubMedCrossRef
8.
Borba LA, Al-Mefty O, Mrak RE et al (1996) Cranial chordomas in children and adolescents. J Neurosurg 84:584–591PubMedCrossRef
9.
Brooks JJ, LiVolsi VA, Trojanowski J (1987) Does chondroid chordoma exist? Acta Neuropathol (Berl) 72:229–235CrossRef
10.
Camacho-Arroyo I, González-Agüero G, Gamboa-Domínguez A et al (2000) Progesterone receptor isoforms expression pattern in human chordomas. J Neurooncol 49(1):1–7PubMedCrossRef
11.
Carpentier A, Polivka M, Blanquet A et al (2002) Suboccipital and cervical chordomas: the value of aggressive treatment at first presentation of the disease. J Neurosurg 97(5):1070–7PubMedCrossRef
12.
Casali PG, Messina A, Stacchiotti S et al (2004) Imatinib mesylate in chordoma. Cancer 101(9):2086–2097PubMedCrossRef
13.
Castro JR, Linstadt DE, Bahary JP et al (1994) Experience in charged particle irradiation of tumors of the skull base: 1977–1992. Int J Radiat Oncol Biol Phys 29:647–655PubMedCrossRef
14.
15.
Chetty R, Levin CV, Kalan MR (1991) Chordoma: a 20-year clinicopathologic review of the experience at Groote Schuur Hospital, Cape Town. J Surg Oncol 46:261–264PubMedCrossRef
16.
Cho YH, Kim JH, Khang SK et al (2008) Chordomas and chondrosarcomas of the skull base: comparative analysis of clinical results in 30 patients. Neurosurg Rev 31(1):35–43PubMedCrossRef
17.
Colli BO, Al-Mefty O (2001) Chordomas of the skull base: follow-up review and prognostic factors. Neurosurg Focus 10(3):E1PubMedCrossRef
18.
Crockard HA, Steel T, Plowman N et al (2001) A multidisciplinary team approach to skull base chordomas. J Neurosurg 95(2):175–183PubMedCrossRef
19.
20.
Dalpra L, Malgara R, Miozzo M et al (1999) First cytogenetic study of a recurrent familial chordoma of the clivus. Int J Cancer 81:24–30PubMedCrossRef
21.
Debus J, Schulz-Ertner D, Schad L et al (2000) Stereotactic fractionated radiotherapy for chordomas and chondrosarcomas of the skull base. Int J Radiat Oncol Biol Phys 47:591–596PubMedCrossRef
22.
Deniz ML, Kiliç T, Almaata I et al (2002) Expression of growth factors and structural proteins in chordomas: basic fibroblast growth factor, transforming growth factor alpha, and fibronectin are correlated with recurrence. Neurosurgery 51(3):753–760PubMed
23.
Dhall G, Traverso M, Finlay JL et al (2010) The role of chemotherapy in pediatric clival chordomas. J Neurooncol 103(3):657–662PubMedCrossRef
24.
Erdem E, Angtuaco EC, Van Hemert R et al (2003) Comprehensive review of intracranial chordoma. Radiographics 23(4):995–1009PubMedCrossRef
25.
Eriksson B, Gunterberg B, Kindblom LG (1981) Chordoma. A clinicopathologic and prognostic study of a Swedish national series. Acta Orthop Scand 52(1):49–58PubMedCrossRef
26.
Fagundes MA, Hug EB, Liebsch NJ et al (1995) Radiation therapy for chordomas of the base of skull and cervical spine: patterns of failure and outcome after relapse. Int J Radiat Oncol Biol Phys 33(3):579–584PubMedCrossRef
27.
Forsyth PA, Cascino TL, Shaw EG et al (1993) Intracranial chordomas: a clinicopathological and prognostic study of 51 cases. J Neurosurg 78(5):741–747PubMedCrossRef
28.
Gay E, Sekhar LN, Rubinstein E et al (1995) Chordomas and chondrosarcomas of the cranial base: results and follow-up of 60 patients. Neurosurgery 36(5):887–896PubMedCrossRef
29.
Gottschalk D, Fehn M, Patt S et al (2001) Matrix gene expression analysis and cellular phenotyping in chordoma reveals focal differentiation pattern of neoplastic cells mimicking nucleus pulposus development. Am J Pathol 158(5):1571–1578PubMedCrossRef
30.
Guiu S, Guiu B, Feutray S et al (2009) Direct intratumoral chemotherapy with carboplatin and epinephrine in a recurrent cervical chordoma: case report. Neurosurgery 65(3):E629–30PubMedCrossRef
31.
Haeckel C, Krueger S, Kuester D et al (2000) Expression of cathepsin K in chordoma. Hum Pathol 31(7):834–840PubMedCrossRef
32.
Heffelfinger MJ, Dahlin DC, MacCarty CS et al (1973) Chordomas and cartilaginous tumors at the skull base. Cancer 32:410–420PubMedCrossRef
33.
Higinbotham NL, Phillips RF, Farr HW et al (1967) Chordoma. Thirty-five-year study at memorial hospital. Cancer 20(11):1841–1850PubMedCrossRef
34.
Holton JL, Steel T, Luxsuwong M et al (2000) Skull base chordoma: correlation of tumor doubling time with age, mitosis and Ki67 proliferation index. Neuropathol Appl Neurobiol 26:497–503PubMedCrossRef
35.
Hu B, McPhaul L, Cornford M et al (1999) Expression of tau proteins and tubulin in extraskeletal myxoid chondrosarcoma, chordoma, and other chondroid tumors. Am J Clin Pathol 112(2):189–193PubMed
36.
Hug EB, Fitzek MM, Liebsch NJ et al (1995) Locally challenging osteo and chondrogenic tumors of the axial skeleton: results of combined proton and photon radiation therapy using three-dimensional treatment planning. Int J Radiat Oncol Biol Phys 31:467–476PubMedCrossRef
37.
Hug EB, Slater JD (2000) Proton radiation therapy for chordomas and chondrosarcomas of the skull base. Neurosurg Clin N Am 11:627–638PubMed
38.
Ji Z, Long H, Hu Y et al (2010) Expression of MDR1, HIF-1alpha and MRP1 in sacral chordoma and chordoma cell line CM-319. J Exp Clin Cancer Res 29(1):158PubMedCrossRef
39.
Kamrin RP, Potanos JN, Pool JL et al (1964) An evaluation of the diagnosis and treatment of chordoma. J Neurol Neurosurg Psychiatry 27:157–165PubMedCrossRef
40.
Keisch ME, Garcia DM, Shibuya RB et al (1991) Retrospective long-term follow-up analysis in 21 patients with chordomas of various sites treated at a single institution. J Neurosurg 75(3):374–377PubMedCrossRef
41.
Kilgore S, Prayson RA (2002) Apoptotic and proliferative markers in chordomas: a study of 26 tumors. Ann Diagn Pathol 6(4):222–228PubMedCrossRef
42.
Kondziolka D, Lunsford LD, Flickinger JC (1991) The role of radiosurgery in the management of chordoma and chondrosarcoma of the cranial base. Neurosurgery 29(1):38–46PubMedCrossRef
43.
Korten A, Berg H, Spincemaille GH et al (1998) Intracranial chondrosarcoma: review of the literature and report of 15 cases. J Neurol Neurosurg Psychiatry 65:88–92PubMedCrossRef
44.
Lanzino G, Dumont AS, Lopes MB et al (2001) Skull base chordomas: overview of disease, management options, and outcome. Neurosurg Focus 10(3):E12PubMedCrossRef
45.
Matsuno A, Sasaki T, Nagashima T et al (1997) Immunohistochemical examination of proliferative potentials and the expression of cell cycle-related proteins of intracranial chordomas. Hum Pathol 28(6):714–719PubMedCrossRef
46.
Menezes AH, Sato Y (1995) Primary tumors of the spine in children—natural history and management. 1990. Pediatr Neurosurg 23(2):101–113PubMedCrossRef
47.
Meyer JE, Oot RF, Lindfors KK (1986) CT appearance of clival chordomas. J Comput Assist Tomogr 10(1):34–38PubMedCrossRef
48.
Meyers SP, Hirsch WL Jr, Curtin HD et al (1992) Chordomas of the skull base: MR features. Am J Neuroradiol 13(6):1627–1636PubMed
49.
Miozzo M, Dalprà L, Riva P et al (2000) A tumor suppressor locus in familial and sporadic chordoma maps to 1p36. Int J Cancer 87(1):68–72PubMedCrossRef
50.
Mori K, Chano T, Kushima R et al (2002) Expression of E-cadherin in chordomas: diagnostic marker and possible role of tumor cell affinity. Virchows Arch 440(2):123–127PubMedCrossRef
51.
Munzenrider JE, Liebsch NJ (1999) Proton therapy for tumors of the skull base. Strahlendher Onkol 175(Suppl 2):57–63CrossRef
52.
Muthukumar N, Kondziolka D, Lunsford LD et al (1998) Stereotactic radiosurgery for chordoma and chondrosarcoma: further experiences. Int J Radiat Oncol Biol Phys 41:387–392PubMedCrossRef
53.
Naka T, Boltze C, Samii A et al (2003) Skull base and nonskull base chordomas: clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability. Cancer 98(9):1934–1941PubMedCrossRef
54.
Naka T, Fukuda T, Chuman H et al (1996) Proliferative activities in conventional chordoma: a clinicopathologic, DNA flow cytometric, and immunohistochemical analysis of 17 specimens with special referente to anaplastic chordoma showing a diffuse proliferation and nuclear atypia. Hum Pathol 27(4):381–388PubMedCrossRef
55.
Naka T, Iwamoto Y, Shinohara N et al (1997) Cytokeratin subtyping in chordomas and the fetal notochord: an immunohistochemical analysis of aberrant expression. Mod Pathol 10(6):545–551PubMed
56.
Naka T, Oda Y, Iwamoto Y et al (2001) Immunohistochemical analysis of E-cadherin, alpha-catenin, beta-catenin, gamma-catenin, and neural cell adhesion molecule (NCAM) in chordoma. J Clin Pathol 54(12):945–950PubMedCrossRef
57.
Nishigaya K, Kaneko M, Ohashi Y et al (1998) Intradural retroclival chordoma without bone involvement: no tumor regrowth 5 years after operation. Case report. J Neurosurg 88(4):764–768PubMedCrossRef
58.
Noel G, Feuvret L, Calugaru V et al (2005) Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. Acta Oncol 44:700–708PubMedCrossRef
59.
O'Connell JX, Renard LG, Liebsch NJ et al (1994) Base of skull chordoma: a correlative study and clinical features of 62 cases. Cancer 74:2261–2267PubMedCrossRef
60.
O'Hara BJ, Paetau A, Miettinen M (1998) Keratin subsets and monoclonal antibody HBME-1 in chordoma: immunohistochemical differential diagnosis between tumors simulating chordoma. Hum Pathol 29(2):119–126PubMedCrossRef
61.
Orzan F, Terreni MR, Longoni M et al (2007) Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas. Oncol Rep 18(1):249–252PubMed
62.
Paavolainen P, Teppo L (1967) Chordoma in Finland. Acta Orthop Scand 47:46–51
63.
Pallini R, Maira G, Pierconti F et al (2003) Chordoma of the skull base: predictors of tumor recurrence. J Neurosurg 98(4):812–822PubMedCrossRef
64.
Pamir MN, Kiliç T, Türe U et al (2004) Multimodality management of 26 skull-base chordomas with 4-year mean follow-up: experience at a single institution. Acta Neurochir (Wien) 146(4):343–354CrossRef
65.
Park SA, Kim HS (2008) F-18 FDG PET/CT evaluation of sacrococcygeal chordoma. Clin Nucl Med 33(12):906–908PubMedCrossRef
66.
Pearlman AW, Friedman M (1970) Radical radiation therapy of chordoma. Am J Roentgenol Radium Ther Nucl Med 108:333–341
67.
Presneau N, Shalaby A, Idowu B et al (2009) Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway. Br J Cancer 100(9):1406–1414PubMedCrossRef
68.
Raffel C, Wright DC, Gutin PH et al (1985) Cranial chordoma: clinical presentation and results of operative and radiation therapy in twenty-six patients. Neurosurgery 17:703–710PubMedCrossRef
69.
Rich TA, Schiller A, Suit HD et al (1985) Clinical and pathologic review of 48 cases of chordoma. Cancer 56:182–187PubMedCrossRef
70.
Riva P, Crosti F, Orzan F et al (2003) Mapping of candidate region for chordoma development to 1p36.13 by LOH analysis. Int J Cancer 107(3):493–497PubMedCrossRef
71.
Roberti F, Sekhar LN, Jones RV et al (2007) Intradural cranial chordoma: a rare presentation of an uncommon tumor. Surgical experience and review of the literature. J Neurosurg 106(2):270–274PubMedCrossRef
72.
Rosenberg AE, Nielsen GP, Keel SB et al (1999) Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma. Am J Surg Pathol 23:1370–1378PubMedCrossRef
73.
Russel DS, Rubinstein LJ (1989) Pathology of tumors of the nervous system. Edward Arnold, London
74.
Samii A, Gerganov VM, Herold C et al (2007) Chordomas of the skull base: surgical management and outcome. J Neurosurg 107(2):319–324PubMedCrossRef
75.
Scheil S, Brüderlein S, Liehr T et al (2001) Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 32(3):203–211PubMedCrossRef
76.
Schwab J, Antonescu C, Boland P et al (2009) Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma. Anticancer Res 29(6):1867–1871PubMed
77.
Sekhar LN, Pranatartiharan R, Chanda A et al (2001) Chordomas and chondrosarcomas of the skull base: results and complications of surgical management. Neurosurg Focus 10(3):E2PubMedCrossRef
78.
Sen C, Triana A (2001) Cranial chordomas: results of radical excision. Neurosurg Focus 10(3):E3PubMedCrossRef
79.
Sen C, Triana AI, Berglind N et al (2010) Clival chordomas: clinical management, results, and complications in 71 patients. J Neurosurg 113(5):1059–1071PubMedCrossRef
80.
Shalaby A, Presneau N, Ye H et al (2011) The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. J Pathol 223(3):336–346PubMedCrossRef
81.
Singhal N, Kotasek D, Parnis FX (2009) Response to erlotinib in a patient with treatment refractory chordoma. Anticancer Drugs 20(10):953–955PubMedCrossRef
82.
Sommer J, Itani DM, Homlar KC et al (2010) Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma. J Pathol 220(5):608–617PubMedCrossRef
83.
Stacchiotti S, Marrari A, Tamborini E et al (2009) Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol 20(11):1886–1894PubMedCrossRef
84.
Stippler M, Gardner PA, Snyderman CH et al (2009) Endoscopic endonasal approach for clival chordomas. Neurosurgery 64(2):268–278PubMedCrossRef
85.
Stüer C, Schramm J, Schaller C (2006) Skull base chordomas: management and results. Neurol Med Chir (Tokyo) 46(3):118–125CrossRef
86.
Suit HD, Goitein M, Munzenrider J et al (1982) Definitive radiation therapy for chordoma and chondrosarcoma of base of skull and cervical spine. J Neurosurg 56:377–385PubMedCrossRef
87.
Tai PT, Craighead P, Bagdon F (1995) Optimization of radiotherapy for patients with cranial chordoma. A review of dose-response ratios for photon techniques. Cancer 75(3):749–756PubMedCrossRef
88.
Tzortzidis F, Elahi F, Wright D et al (2006) Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordomas. Neurosurgery 59(2):230–237PubMedCrossRef
89.
Volpe NJ, Liebsch NJ, Munzenrider JE et al (1993) Neuro-ophthalmologic findings in chordoma and chondrosarcoma of the skull base. Am J Ophthalmol 115:97–104PubMed
90.
Walker WP, Landas SK, Bromley CM et al (1991) Immunohistochemical distinction of classic and chondroid chordomas. Mod Pathol 4(5):661–666PubMed
91.
Warnick RE, Raisanen J, Kaczmar T Jr et al (1991) Intradural chordoma of the tentorium cerebelli. Case report. J Neurosurg 74(3):508–511PubMedCrossRef
92.
Watkins L, Khudados ES, Kaleoglu M et al (1993) Skull base chordoma: a review of 38 patients, 1958–88. Br J Neurosurg 7:241–248PubMedCrossRef
Metadaten
Titel
Current therapeutic options and novel molecular markers in skull base chordomas
verfasst von
Filippo Gagliardi
Nicola Boari
Paola Riva
Pietro Mortini
Publikationsdatum
01.01.2012
Verlag
Springer-Verlag
Erschienen in
Neurosurgical Review / Ausgabe 1/2012
Print ISSN: 0344-5607
Elektronische ISSN: 1437-2320
DOI
https://doi.org/10.1007/s10143-011-0354-1

Weitere Artikel der Ausgabe 1/2012

Neurosurgical Review 1/2012 Zur Ausgabe

Acknowledgement to Referees

Referees 2011

Original Article

Dual-room 1.5-T intraoperative magnetic resonance imaging suite with a movable magnet: implementation and preliminary experience

Original Article

Percutaneous transluminal angioplasty for atherosclerotic stenosis of the subclavian or innominate artery: angiographic and clinical outcomes in 36 patients

Original Article

Anterior inferior cerebellar artery aneurysms: six cases and a review of the literature

Letter to the Editor

A comment on “Contralateral cerebral hemodynamic changes after unilateral direct revascularization in patients with moyamoya disease”

Review

Management of oculomotor nerve schwannomas in two different locations: surgical nuances and comprehensive review

Neu im Fachgebiet Chirurgie

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Hochrisiko-Eingriffe für postoperative Übelkeit

16.04.2024 | HNO-Chirurgie | Nachrichten

HNO-Op. auch mit über 90?

16.04.2024 | Infektiologie | Nachrichten

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

10.04.2024 | Postoperative Schmerztherapie | Nachrichten

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom CME-Kurs
CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur CME-Kurs
CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis CME-Kurs
CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.